Tissue Regenix Group PLC Expands US GPO coverage for DermaPure
April 04 2019 - 2:26AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
04 April 2019
Tissue Regenix Group plc
Expands US GPO coverage for DermaPure into 1,500 additional
hospitals
Leeds, 04 April 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group"), a regenerative medical devices company,
announced that it has secured additional coverage with a US Group
Purchasing Organization (GPO) for the use of DermaPure, a
decellularized allograft dermis.
The additional coverage will open up access to a further 1,500
hospitals and 32,500 alternative care providers, primarily in the
South Eastern region of the US, bolstering the commercial
opportunity in Florida, the second largest State with regard to the
use of biological tissues such as the DermaPure product.
This expansion builds on Tissue Regenix's contracts with the two
largest GPOs in the US, Premier, Inc. and Vizient, Inc., and with
the addition of this new agreement increases potential DermaPure
availability into 95% of institutions that purchase via large GPO
networks, allowing patients and physicians potential to access the
clinical and health economic benefits provided by DermaPure.
Gareth Jones, interim COO of Tissue Regenix Group commented:
"GPO approvals play a fundamental role in the Group's
commercialisation strategy for DermaPure, in order to bring this
important treatment option to more patients. Another successful
approval from a GPO reflects the positive changes we made to our
commercial sales strategy where we realigned our efforts to drive
adoption directly in the hospital space. This recent approval will
provide a more regional focus across the US landscape, furthering
our US market penetration efforts."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson, Head of Communications 07920272 441
--------------------------------------------- ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Victoria Foster Mitchell
/ Mary Whittow
============================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUPPCUPBUQC
(END) Dow Jones Newswires
April 04, 2019 02:26 ET (06:26 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024